INTRODUCTION {#S6}
============

Anaplastic lymphoma kinase- *(ALK-)* rearrangement is a therapeutically tractable oncogenic driver that occurs in 2--7% of patients with non-small-cell lung cancer (NSCLC).^[@R1]^ To date, three ALK-targeted small-molecule tyrosine kinase inhibitors have been approved by several health authorities.^[@R2]--[@R5]^ The first ALK-targeted therapeutic was crizotinib, which targets cMET, ALK, and ROS1.^[@R6],[@R7]^ Two phase 3 studies comparing crizotinib with chemotherapy in patients with advanced *ALK*-rearranged NSCLC demonstrated progression-free survival (PFS) and response rate benefits with crizotinib therapy in both second- and first-line settings.^[@R8],[@R9]^ However, most responders acquire resistance within 1 year, with recurrence commonly occurring in the brain or liver.^[@R10]--[@R12]^ In a recent retrospective analysis of patients with *ALK*-rearranged NSCLC treated with crizotinib, the site of disease progression was brain in 41% of patients, and liver in 25% of patients.^[@R11]^ The high incidence of recurrence in the brain may partly be a result of limited blood-brain barrier penetration of crizotinib, which has been described in the clinical setting.^[@R13],[@R14]^ Crizotinib resistance can result from both *ALK*-dependent and *ALK*-independent mechanisms.^[@R10],[@R15],[@R16]^ Therefore, treatment options for patients who progress on crizotinib are needed.^[@R17]^

Ceritinib (LDK378, Novartis Pharmaceuticals) is a potent and selective oral tyrosine kinase inhibitor of ALK (ALKi).^[@R18]^ *In vitro*, ceritinib inhibits ALK with a 20-fold greater potency than crizotinib, and has nanomolar potency against patient-derived crizotinib-resistant tumour cell lines.^[@R19]^ In preclinical xenograft studies, immediate tumour regrowth was observed following completion of crizotinib treatment, whereas regrowth upon stopping ceritinib treatment was notably delayed.^[@R19]^ Further, in a tissue distribution study utilising a rat model, ceritinib crossed the blood-brain barrier with a brain-to-blood exposure (AUC~inf~) ratio of approximately 15%.^[@R20]^ Consistent with these preclinical observations, ceritinib has demonstrated efficacy against crizotinib-resistant tumours in patients with *ALK*-rearranged NSCLC, including brain metastases.^[@R18]^

Preliminary efficacy and safety data from the dose-escalation phase of the ASCEND-1 study have been reported previously.^[@R18]^ The objective of the analyses reported here was to present updated results evaluating antitumour efficacy for a larger cohort of 246 patients with *ALK*-rearranged NSCLC, including both ALKi-naïve and ALKi-pretreated patients, treated at the recommended dose (RD) of 750 mg/day, with a longer median duration of follow-up of 11·1 (interquartile range \[IQR\] 6·7--15·2) months. The majority of patients were heavily pretreated (chemotherapy and/or ALKi). In addition, results from a retrospective review of brain MRI and CT scans conducted to assess intracranial activity are reported for patients with treated and untreated neurologically stable brain metastases at study entry.

METHODS {#S7}
=======

Study design and participants {#S8}
-----------------------------

The study methods for the phase 1, multicentre, open-label ASCEND-1 study have been published previously (see appendix page 1 for a list of study centres).^[@R18]^ Briefly, eligible patients had *ALK*-rearranged NSCLC, were ≥18 years old, had locally advanced or metastatic NSCLC that had progressed (by physician assessment) despite standard therapy (including chemotherapy or ALKi) or for which no effective standard therapy existed, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2, adequate organ function and laboratory results (required laboratory tests: neutrophil count, haemoglobin, platelets, serum total bilirubin, aspartate aminotransferase, alanine aminotransferase, calculated creatinine clearance, serum amylase, serum lipase, and fasting plasma glucose) and a life expectancy of ≥12 weeks. Patients were required to have at least one measurable lesion at baseline according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.0. Patients with untreated or locally treated asymptomatic and stable (\>4 weeks) central nervous system (CNS) disease were eligible. Patients with tumours other than NSCLC were permitted to be enrolled on the study; data from these patients were reported previously^[@R18]^ and were not included in the analysis described here.

Patients were not permitted to have received any chemotherapy, biologic therapy, or other investigational agent for 1--4 weeks (depending upon half-life) prior to starting ceritinib, or during the study. Patients with unresolved nausea, vomiting or diarrhoea (\>Common Terminology Criteria for Adverse Events \[CTCAE\] grade 1), impairment of gastrointestinal function, a history of pancreatitis, liver disease, known HIV, clinically significant cardiac disease, prior or current second malignancy (other than adequately treated in situ carcinoma of the cervix, non-melanoma carcinoma of the skin, or any other curatively treated malignancy that has not recurred in the prior 3 years), and patients with symptomatic, neurologically unstable CNS disease were not eligible for inclusion.

Conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice, the study was approved by the local human investigations committee at each study centre; all patients provided written informed consent prior to screening.

Procedures {#S9}
----------

Patients with *ALK*-rearranged NSCLC were treated with ceritinib, administered orally in fasted patients at the RD of 750 mg/day in continuous 21-day treatment cycles. Treatment was continued until objective evidence of disease progression (treatment beyond progression was permitted in patients who continued to experience a clinical benefit), development of intolerable side effects, or withdrawal of consent. Dose adjustments were permitted for patients who experienced dose-limiting toxicity. In patients with a dose delay of more than 21 days due to ceritinib-related toxicity, treatment was discontinued unless the patient demonstrated evidence of a clinical benefit. Patients were permitted a maximum of three dose-reductions, after which they were required to discontinue treatment.

At baseline, imaging scans of the brain, chest, and abdomen were performed in all patients. During treatment, tumour response was assessed every 6 weeks (RECIST 1.0) to determine overall response rate (ORR), duration of response (DOR), and PFS. Responses were assessed only for patients with measurable disease at baseline and at least one post-baseline assessment. Routine follow-up brain MRI/CT scans were conducted only in patients with brain metastases at study entry. Efficacy was also assessed by a blinded independent review committee (BIRC).

Outcomes {#S10}
--------

After determination of maximum tolerated dose (MTD)/RD, which was the primary objective of the ASCEND-1 trial and has been reported previously,^[@R18]^ the study objectives were to evaluate antitumour efficacy (by investigator and by BIRC) and safety of ceritinib at the RD of 750 mg/day in patients with *ALK*-rearranged NSCLC.

The primary endpoint of the ASCEND-1 study was determination of MTD/RD, which has been reported previously.^[@R18]^ Secondary endpoints reported here include ORR, DOR, and PFS (by investigator and by BIRC). ORR was defined as the proportion of patients with complete response (CR) or partial response (PR), as assessed by whole-body (all sites of disease, including brain) responses (RECIST 1.0 criteria). Responses had to be confirmed by repeat assessments ≥4 weeks after response criteria were first met. DOR was defined as the time from first documented PR or CR to the date of first disease progression or death from any cause. PFS was defined as the time from start of treatment with ceritinib to the date of radiologically documented disease progression or death from any cause.

A retrospective central review was conducted by two independent neuroradiologists (blinded to investigator and BIRC assessment) according to RECIST 1.1; 94 patients had brain metastases at baseline confirmed by retrospective reading of MRI/CT scans and at least one post-baseline MRI/CT tumour assessment (n=20 by CT and n=74 by MRI). A further 30 patients with brain metastases at baseline, as assessed by the investigator, were excluded from the retrospective analysis due to no available baseline (n=8) or post-baseline (n=7) image for review, no consent for central review (n=2), no post-baseline assessment (either in brain or elsewhere; n=6), or because the image was deemed non-assessable by the neuroradiologists (n=7). Brain lesions with longest diameter ≥10 mm were defined as measurable. Prior radiotherapy information, including time from the last dose to start of ceritinib treatment, was collected.

All adverse events (AEs) reported during the study were recorded and graded according to the CTCAE 4.03. Assessments of laboratory parameters, ECOG PS, and overall physical condition were performed at baseline, days 1, 2, 8, and 15 of cycle 1, days 1, 2, and 15 of cycle 2, days 1 and 15 of cycles 3--6, and day 1 of each cycle thereafter, until end of treatment. Assessments were also performed at the end of study/time of withdrawal.

Statistical analysis {#S11}
--------------------

For determination of the MTD/RD (primary objective, dose-escalation phase, reported previously),^[@R18]^ no formal statistical power calculations to determine sample size were performed. For the dose-escalation phase of this study, it was estimated that 40 subjects would be enrolled including at least 6 subjects treated at the MTD level. For the expansion phase of this study, up to 310 patients were planned to be enrolled (including all patients treated at the MTD/RD during the dose-escalation phase who were eligible for the safety set) with at least 25 and up to 100 patients in each of the following patient groups: ALKi-naïve patients, ALKi-pretreated patients who progressed during prior ALKi treatment and ALKi-pretreated patients who did not progress during prior ALKi treatment. Approximately 10 patients were planned to be enrolled with tumours other than NSCLC. In general, preliminary evidence of antitumour activity of ceritinib would be demonstrated if the lower bound of the 95% credible interval is greater than 10% at the MTD/RD within that patient group. Given a sample size of 25 patients per arm, assuming observed ORR of 28%, the 95% credible interval would be (12.6%, 45.7%). Given a sample size of 100 patients per arm, assuming observed ORR of 25% the 95% credible interval would be (17.0%, 33.7%).

Investigator-assessed efficacy and safety assessments included all patients with *ALK*-rearranged NSCLC enrolled on the study who received at least one 750 mg dose of ceritinib (n=246). Data were summarised using descriptive statistics (continuous data) and/or contingency tables (categorical data) for demographic and baseline characteristics, efficacy measurements, and safety measurements. The data cut-off date was 14 April 2014. This study is registered with [ClinicalTrials.gov](http://ClinicalTrials.gov), number NCT01283516.

In addition to assessment of ORR, DOR, and PFS, overall survival (OS) was evaluated, defined as time from start of treatment with ceritinib to date of death from any cause. Time to response was defined as time from start of treatment with ceritinib to first objective tumour response (CR or PR) that was subsequently confirmed. The median DOR, PFS, and OS times, and their associated 95% confidence intervals (CIs), were estimated using Kaplan-- Meier methodology.

Intracranial responses were assessed as CR, PR, or stable disease (SD; defined as non-CR/non-progressive disease \[PD\] for patients with non-measurable lesions) according to RECIST 1.1. Endpoints included overall intracranial response rate (OIRR; CR+PR), intracranial disease control rate (IDCR; CR+PR+SD), and time to intracranial response (time from start of treatment with ceritinib to first objective intracranial response that was subsequently confirmed). Intracranial DOR was defined as time from first complete or partial intracranial response to intracranial disease progression (not considering extracranial disease progression) or death.

Role of the funding source {#S12}
--------------------------

This study was funded by Novartis Pharmaceuticals Corporation. It was designed by Novartis Pharmaceuticals Corporation, study investigators, and an independent steering committee. Data were collected by investigators and analysed by Novartis Pharmaceuticals Corporation. All authors (DWK, RM, DSWT, EF, LQMC, DRC, JV, SS, TDP, GJR, BJS, JW, MT, MS, GL, AS, SS, SL, TS, AY, ATS) had full access to the data, and contributed to the development of and approved the manuscript for submission. The corresponding author had full access to all of the data and the final responsibility to submit for publication.

RESULTS {#S13}
=======

This global phase 1 trial included 255 patients enrolled between Jan 24, 2011 and Jul 31, 2013 across 20 centres who received at least one dose of ceritinib at the 750 mg/day RD. Of these, 246 (96·5%) had *ALK*-rearranged NSCLC; 83 (33·7%) of 246 were ALKi-naïve patients and 163 (66·3%) of 246 were ALKi-pretreated patients ([Figure 1](#F1){ref-type="fig"}). Baseline demographics ([Table 1](#T1){ref-type="table"}) were consistent with those reported in other studies for patients with ALK-rearranged NSCLC, ^[@R6],[@R21]^ and were mostly similar across both patient groups, apart from a numerically larger proportion of Asian patients, lower incidence of baseline brain metastases, and fewer prior treatment regimens in the ALKi-naïve group compared with the ALKi-pretreated group. Overall, the majority of patients were heavily pretreated, having received multiple antineoplastic therapies (chemotherapy and/or ALKi; [Table 1](#T1){ref-type="table"}).

At study entry, 124 patients with *ALK*-rearranged NSCLC had asymptomatic or controlled brain metastases (see appendix page 2), of whom 83 (66·9%) had received prior brain radiotherapy. Baseline patient characteristics for patients with and without brain metastases were mostly similar (see appendix pages 3 and 4), although the latter group appeared to have better ECOG PS and fewer prior lines of antineoplastic therapy.

Based on investigator assessment of whole-body efficacy (all sites of disease, including brain; [Table 2](#T2){ref-type="table"}), the ORR for ALKi-naïve patients was 72·3% (60/83; 95% CI 61·4--81·6), and for ALKi-pretreated patients, 56·4% (92/163; 95% CI 48·5--64·2). Of the 83 ALKi-naïve patients, 16 (19.3%) had received no prior systemic anti-neoplastic therapy; the ORR for these treatment-naïve patients was 68.8% (11/16; 95% CI 41.3--89.0). Median time to response was 6·1 weeks for both ALKi-naïve (range 3·0--42·1 weeks) and ALKi-pretreated (range 4·6--24·1 weeks) patients. Among patients with measurable disease at baseline and at least one post-baseline assessment, a decrease from baseline in tumour burden was observed for the majority of ALKi-naïve and ALKi-pretreated patients ([Figure 2A and 2B](#F2){ref-type="fig"}).

For ALKi-naïve patients, median DOR and PFS were 17·0 (95% CI 11·3--non-estimable \[NE\]) and 18·4 (95% CI 11·1--NE) months, respectively ([Figure 2C](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}); median OS had not yet been reached (95% CI 19·6--NE), but 12-month OS rate was 83·0% (95% CI 72·4-- 89·8). ALKi-pretreated patients had median DOR and PFS of 8·3 (95% CI 6·8--9·7) and 6·9 (95% CI 5·6--8·7) months, respectively ([Figure 2D](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}), and median OS of 16·7 months (95% CI 14·8--NE); the 12-month OS rate was 67·2% (95% CI 58·9--74·1). The median duration of follow-up for overall survival at data cut-off (14 April 2014) was 11·1 (IQR 6·7-- 15·2) months.

In patients who progressed while on ceritinib, treatment was continued beyond disease progression (defined as ceritinib treatment for more than 3 weeks following documentation of PD) in 12 (14·5%) of 83 ALKi-naïve and 48 (29·4%) of 163 ALKi-pretreated patients. At time of data cut-off, treatment was ongoing in 5 (41·7%) of these 12 ALKi-naïve patients, with the remaining 7 (58·3%) patients having discontinued due to PD. Of the 48 ALKi-pretreated patients, treatment was ongoing in 18 (37·5%) patients, with the remaining patients having discontinued due to PD (n=25; 52·1%), AEs (n=1; 2·1%), lost to follow-up (n=1; 2·1%), and withdrawn consent (n=3; 6·3%). At time of data cut-off, death was reported for two of seven ALKi-naïve and 14 of 30 ALKi-pretreated patients who had discontinued following treatment beyond disease progression.

Whole-body responses for ALKi-naïve and ALKi-pretreated patients with brain metastases at study entry (n=124) were similar to those of the full patient population, with the same pattern of PFS and DOR times (see appendix page 5).

The results of BIRC assessment for efficacy were consistent with the results of the investigator-assessed efficacy analyses (see appendix page 6).

Given the evidence for whole-body response to ceritinib in patients with brain metastases at study entry, retrospective analyses were conducted to specifically evaluate intracranial responses in this subgroup. Of the 124 patients with baseline brain metastases by investigator assessment, brain metastases were retrospectively confirmed by independent neuroradiologists for 94 patients with baseline and at least one post-baseline MRI/CT tumour assessment.

Median time to intracranial response was 6·1 weeks (range 5·1--30·1), consistent with that reported for whole-body responses in the full patient population (n=246). For ALKi-naïve (n=19) and ALKi-pretreated (n=75) patients, median time to intracranial response was 9·9 (range 5·4--30·1) and 6·1 (range 5·1--19·1) weeks, respectively (see appendix page 7). Based on central review by two independent neuroradiologists, ceritinib treatment resulted in an IDCR of 78·9% (15/19; 95% CI 54·4--93·9) in ALKi-naïve patients and 65·3% (49/75; 95% CI 53·5--76·0) in ALKi-pretreated patients with baseline brain metastases ([Table 3](#T3){ref-type="table"}).

Of the 94 patients included in the retrospective analysis, 63 (67·0%) had previously received radiotherapy to the brain (see appendix page 8). In the 31 (33·0%) of 94 patients who had not previously received radiotherapy to the brain, IDCR (CR+PR+SD) was observed in 7 of 8 ALKi-naïve patients and 15 of 23 ALKi-pretreated patients. This IDCR was comparable to those patients previously treated with radiotherapy.

Based on RECIST 1.1, 36 of 94 patients had measurable intracranial lesions at baseline; for these, the IDCR was 62·5% (5/8; 95% CI 24·5--91·5) in ALKi-naïve patients and 60·7% (17/28; 95% CI 40·6--78·5) in ALKi-pretreated patients ([Table 3](#T3){ref-type="table"}). The median intracranial DOR in patients with measurable disease was 8·2 months (95% CI 5·6--NE) in ALKi-naïve and 11 1 months (95% CI 2·8--NE) in ALKi-pretreated patients. The majority of patients with measurable brain lesions at baseline had received prior radiotherapy to the brain (25/36; 69·4%); 17 of these had received the last radiotherapy treatment more than 3 months prior to starting ceritinib treatment (see appendix page 9). Among 11 patients (4 ALKi-naïve, 7 ALKi-pretreated) with measurable brain lesions at baseline who had not received prior brain radiotherapy, six achieved a PR ([Table 3](#T3){ref-type="table"}, see appendix page 9). Intracranial responses were similar in those patients who had received prior brain radiotherapy, regardless of timing of radiotherapy (≥3 months *vs* \<3 months prior to starting ceritinib).

Median duration of exposure to ceritinib 750 mg/day for all 246 patients was 38·6 (range 0·4--105·9) weeks, with a median average daily dose of 664.2 mg (range 357·9--750·0 mg) and median relative dose intensity of 82·8% (range 30·2--100%). Overall, 181 (73·6%) of 246 patients had at least one dose interruption, and 152 (61·8%) of 246 patients had at least one dose reduction. Dose reductions occurred throughout the dosing period (see appendix page 10) with 88 (35·8%) of 246 patients having one dose reduction, 48 (19·5%) two dose reductions, and 16 (6·5%) three or more dose reductions. In patients who discontinued ceritinib treatment, regardless of primary reason, 19 (22·9%) of 83 ALKi-naïve and 43 (26·4%) of 163 ALKi-pretreated patients received further anti-neoplastic therapy following discontinuation (see appendix page 11). However, data on anti-neoplastic therapy following discontinuation were collected for only 28 days following discontinuation, limiting the clinical interpretation of these data.

In all patients with brain metastases at baseline (n=124) and in those included in the retrospective analysis (n=94; [Figure 3](#F3){ref-type="fig"}), duration of exposure to ceritinib 750 mg/day was similar to that reported for all 246 patients (see appendix page 12).

In the 60 patients who continued ceritinib 750 mg/day beyond disease progression, the median post-progression exposure was 10·1 (range 3·3--71·7) weeks.

All patients with *ALK*-rearranged NSCLC treated at 750 mg/day (n=246) experienced at least one AE; 96.7% (238/246) were suspected to be drug-related. The most frequent AEs are presented in [Table 4](#T4){ref-type="table"}; gastrointestinal (GI) toxicity was most common (\>60% of patients, mostly grade 1/2), including diarrhoea, nausea, and vomiting, generally occurring early in treatment (median time to onset, days \[quartiles 1, 3\]: 4 \[1, 13\], 8 \[1, 22\], and 8 \[2, 32\], respectively). These common GI toxicities were manageable through administration of concomitant medication and, where required, dose modification. One (0·4%) of the 246 patients discontinued ceritinib because of a GI AE (grade 1 nausea).

Grade 3/4 AEs (regardless of study drug relationship; [Table 4](#T4){ref-type="table"}; see appendix pages 13--15) were reported for 200 (81·3%) of 246 patients and serious AEs (SAEs) for 117 (47·6%) of 246 patients. Grade 3/4 AEs and SAEs (of any grade) suspected to be drug-related were experienced by 125 (50·8%) and 29 (11·8%) of 246 patients, respectively. Grade 3/4 increases (regardless of study drug relationship) in alanine aminotransferases and aspartate aminotransferases were reported for 73 (29·7%) and 25 (10·2%) of 246 patients, respectively, but were manageable through dose interruption until resolution; there were no cases of Hy's law in this study. Although grade 3/4 lipase increase was reported in 16 (6·5%) of 246 patients, there were no cases of increased lipase as an SAE, nor did any patients discontinue treatment as a result of this AE.

Hyperglycaemia was reported at grade 3/4 for 15 (6·1%) of 246 patients, and as an SAE in 6 (2·4%) patients; no patients discontinued treatment due to AE/SAEs associated with hyperglycaemia. Diabetic ketoacidosis (not suspected to be study drug related) was reported at grade 3 in one patient; no action was taken with the study drug and the AE resolved, without recurrence of hyperglycaemia. Interstitial lung disease (ILD)/pneumonitis was reported for 9 (3·7%) of 246 patients, leading to treatment discontinuation in 3 (1·2%) patients; one case was fatal. There were no cases of grade 3/4 bradycardia. There were no cases of corrected QT interval \>500 ms; changes from baseline of the corrected QT interval \>60 ms occurred in 8 (3·3%) of 246 patients. Overall, 26 (10·6%) of 246 patients discontinued treatment due to AEs, of which nine were suspected to be related to study drug. Two on-treatment deaths were considered related to study drug, one due to ILD (noted above) and the other due to multi-organ failure that occurred in the context of infection and ischaemic hepatitis.

AEs in patients with brain metastases at baseline (n=124) were largely consistent with those reported for the full study population (see appendix page 16).

DISCUSSION {#S14}
==========

Ceritinib treatment resulted in clinically meaningful, rapid, and durable antitumour responses in both ALKi-naïve and ALKi-pretreated patients with *ALK*-rearranged NSCLC, most of whom had received multiple prior lines of antineoplastic therapy. In addition, ceritinib antitumour activity was demonstrated in patients with asymptomatic or controlled baseline brain metastases, with both extracranial and intracranial responses observed.

Despite initial efficacy, development of resistance to crizotinib (and other targeted therapeutics) remains an ongoing challenge that has limited the benefit in patients with NSCLC.^[@R10],[@R15],[@R22],[@R23]^ The first-in-human phase 1 study of crizotinib evaluated 143 patients with advanced stage *ALK*-rearranged NSCLC who had not previously received treatment with an ALKi. In these ALKi-naïve patients, who had baseline characteristics consistent with those reported for other trials in patients with ALK-rearranged NSCLC, ^[@R8],[@R21]^ the ORR was 60·8% and median PFS was 9·7 months.^[@R7]^ In the updated analysis of ceritinib activity in the ASCEND-1 study reported here, those patients who were ALKi-naïve achieved an ORR of 72·3% and median PFS of 18·4 months. Moreover, the median PFS in these patients was longer than that reported for patients treated with crizotinib post-chemotherapy (7·7 months),^[@R8]^ and for patients who received crizotinib as first-line therapy (10·9 months) in the recently published phase 3 PROFILE 1014 trial.^[@R9]^ Of note, patients in the crizotinib PROFILE 1014 study were systemic treatment naïve; in the ASCEND-1 study, 81% of ALKi-naïve patients had received at least one line of prior antineoplastic therapy.

Patients who were ALKi-pretreated also achieved responses following treatment with ceritinib; the ORR in these patients was 56·4% and median PFS was 6·9 months. In this patient subgroup, over half of the patients had received at least three prior lines of therapy. The observed response is consistent with that reported for another phase 1 study (conducted in the USA) investigating the second-generation ALKi alectinib in patients previously treated with crizotinib; the ORR in this study was 55%.^[@R21]^

The high ORR and median DOR reported with ceritinib in this study, particularly in ALKi-naïve patients (72·3% and 17.0 months, respectively), are indicative of durable responses. Overall, outcomes in patients with advanced NSCLC are poor, with first-line chemotherapy reporting ORRs in the range of 28--45% and DORs of 4·5--5·3 months.^[@R9],[@R24]^ Responses with targeted therapies in patients with NSCLC with oncogenic driver mutations are consistently higher.^[@R25]^ Nonetheless, in the first-in-human phase 1 study of crizotinib, ORR was 60·8%, with a corresponding DOR of 49·1 weeks.^[@R7]^

Brain metastases have been reported on diagnosis in around 24% of patients with advanced ALK-rearranged NSCLC, making activity in the brain an important feature of ALK-targeted therapies.^[@R26]^ Despite evidence for potential clinical benefit of crizotinib in patients with baseline brain metastases,^[@R27]^ the brain is the most common site of disease progression following acquired resistance to crizotinib.^[@R11],[@R12]^ Further, in a retrospective pooled analysis of two crizotinib trials (PROFILE 1005 and 1007), the OIRR with crizotinib was substantially lower (18%) than the extracranial response rate (53%).^[@R28]^ The limited activity reported for crizotinib in the brain may be related to lower concentrations of the drug in cerebrospinal fluid compared with the plasma concentration (0·616 ng/ml compared with 237 ng/ml, respectively, 5 hours after a 250 mg dose).^[@R13]^

Brain metastases are associated with a poor prognosis. In the general NSCLC population, survival is rarely extended beyond 12 months, and median PFS times fall in the range of 3--6 months.^[@R29]--[@R31]^ Local ablative therapy is an option for patients with *ALK*-rearranged NSCLC receiving crizotinib who have progression in the brain.^[@R12]^ However, recent data suggest that second-generation ALK inhibitors demonstrate both extracranial and intracranial antitumour activity,^[@R21],[@R32]^ representing an alternative to local ablative therapy. Nonetheless, these data should be interpreted with caution, as the contribution of prior radiotherapy to efficacy outcomes in this patient population is unknown.

This retrospective central analysis of intracranial responses was conducted in patients with baseline brain metastases who were asymptomatic or had stable CNS disease. As it was carried out retrospectively, this analysis has some limitations, including that the pre-defined study assessments, data collection schedule, and sample size were not specifically designed to evaluate this endpoint. Nevertheless, there was promising evidence of intracranial activity, with a high IDCR being achieved, in both ALKi-naïve (78·9%) and ALKi-pretreated (65·3%) patients. Moreover, the median time to intracranial response was similar to that reported for whole-body responses. As radiotherapy is often used to treat brain lesions,^[@R31]^ 67% of patients included in the central analysis had previously received radiotherapy to the brain (although, as a retrospective analysis, whether radiotherapy was whole-brain or stereotactic was not recorded). Nonetheless, 6/11 patients with measurable brain disease were radiotherapy-naïve and achieved a PR, indicative of blood-brain barrier penetration of this highly potent ALK inhibitor.^[@R20]^ A confirmatory phase II clinical trial, which is expected to enrol approximately 125 patients, is ongoing to evaluate ceritinib activity in patients with ALK-rearranged NSCLC and metastases to the brain or leptomeninges (NCT02336451). Patients will be stratified according to prior ALKi treatment (pretreated or naïve), whether or not they have received prior whole-brain radiotherapy and leptomeningeal disease.

Longer follow-up shows that the safety profile for ceritinib is similar to that reported previously, and is broadly consistent in patients with or without brain metastases.^[@R18]^ GI AEs, mostly grade 1/2, are the most frequent AEs following ceritinib treatment. These AEs were manageable (only one patient discontinued ceritinib due to a GI AE) and highlight the potential need for early, proactive management and patient education.^[@R33]^ It is not possible to directly compare AE frequency between different studies, limiting the direct comparison of AEs between ceritinib and crizotinib. Common side-effects listed for crizotinib include diarrhoea and nausea, reported in approximately 50--60% of patients, and visual disorders in approximately 60% of patients.^[@R7],[@R8]^ Elevated liver aminotransferases have also been reported as a common side effect with crizotinib; however, this appears more variable.^[@R7],[@R8]^ In the study reported here, grade 3/4 elevations in liver enzymes were common, but manageable through dose interruption or reduction (after which patients could resume ceritinib treatment). ILD/pneumonitis, also a known complication of crizotinib treatment,^[@R8]^ was reported for a small proportion of patients in this study. Overall, rates of discontinuation due to AEs with ceritinib were low. In addition, data on patient-reported outcomes from ongoing phase 2 studies (including both patients previously treated with crizotinib and ALKi-naïve patients) have shown that quality of life is maintained, with reductions in lung symptoms during the course of treatment with ceritinib.^[@R34],[@R35]^

In this 1-year follow-up to the ASCEND-1 study, treatment with ceritinib 750 mg/day continued to result in a high rate of rapid, durable responses and prolonged PFS in ALKi-naïve and ALKi-pretreated patients, along with a manageable safety profile and low rates of study discontinuation. A high level of response was observed in patients with and without baseline brain metastases. Furthermore, intracranial responses were high, including in patients with measurable brain lesions that were radiotherapy-naïve. Taken together, these data expand our understanding of the efficacy and safety of ceritinib and its role in the management of patients with *ALK*-rearranged NSCLC.
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![Patient disposition\
Denominator used for ^a^ = 255, ^b^ = 246, ^c^ = 163, ^d^ = 83.\
AE=adverse event. ALK=anaplastic lymphoma kinase. NSCLC=non-small-cell lung cancer.\
\* The total number of ALKi-pretreated and ALKi-naïve patients who discontinued treatment due to AEs were 18 and 8 patients, respectively. However, for one patient from each group, an AE was not considered the primary reason for discontinuation, and as such the number of patients listed in the patient disposition are 17 and 7, respectively.](nihms820486f1){#F1}

###### Best percentage change from baseline in tumour volume

\(A\) ALKi-naïve patients (n=77) and (B) ALKi-pretreated patients (n=151); upper dotted line indicates threshold for disease progression (PD), lower dotted line represents the threshold of a 30% decrease from baseline (patients with a PR or CR will meet or exceed this threshold) and where the changes fall between the two dotted lines, SD is defined; \*n=number of patients with measurable disease at baseline and at least one valid post baseline tumour assessment. (C) Duration of response in all patients with *ALK*-rearranged NSCLC who responded to ceritinib treatment (N=152) (D) Progression-free survival in all patients with *ALK*-rearranged NSCLC (N=246)

ALK=anaplastic lymphoma kinase. CR=complete response. PR=partial response. SD=stable disease.
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![Exposure and response to ceritinib\
Duration of exposure and response to ceritinib in patients with *ALK*-rearranged NSCLC with brain metastases at baseline by MRI/CT (retrospective, independent readings; n=94). Whether or not the patient received prior radiotherapy to the brain is indicated on the plots; in patients who did received prior radiotherapy, the duration between last radiotherapy treatment and start of ceritinib treatment (≥ or \< than 3 months) is also indicated.\
ALK=anaplastic lymphoma kinase. BIOR=best intracranial overall response. CR=complete response. NCRNPD=non-complete response non-progressive disease. NSCLC=non-small cell lung cancer. PD=progressive disease. PR=partial response. RT=radiotherapy. SD=stable disease. UNK=unknown.](nihms820486f3){#F3}

###### 

Patient baseline characteristics in all patients with *ALK*-rearranged NSCLC (N=246)

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                                 ALKi-naïve\        ALKi-pretreated[\*](#TFN2){ref-type="table-fn"}\
                                                                                  (n=83)             (n=163)
  ------------------------------------------------------------------------------- ------------------ --------------------------------------------------
  Age, median (range), years                                                      55 (22--80)        52 (24--80)

  Sex, n (%)                                                                                         

    Female                                                                        44 (53·0)          88 (54·0)

  WHO/ECOG performance status, n (%)                                                                 

    0                                                                             25 (30·1)          38 (23·3)

    1                                                                             51 (61·4)          104 (63·8)

    2                                                                             7 (8·4)            20 (12·3)

    ≥3                                                                            0                  1 (0·6)

  Smoking history                                                                                    

    Never/ex-smoker                                                               82 (98·8%)         158 (97·0%)

    Current smoker                                                                1 (1·2%)           5 (3·1%)

  Race, n (%)                                                                                        

    Caucasian                                                                     48 (57·8)          108 (66·3)

    Black                                                                         0                  4 (2·5)

    Asian                                                                         35 (42·2)          47 (28·8)

    Other                                                                         0                  4 (2·5)

  Tumour histology/cytology, n (%)                                                                   

    Adenocarcinoma                                                                76 (91·6)          152 (93·3)

  Other                                                                           7 (8·4)            11 (6·7)

  Site of metastasis, n (%)                                                                          

    Brain                                                                         26 (31·3)          98 (60·1)

    Lung                                                                          62 (74·7)          111 (68·1)

    Liver                                                                         30 (36·1)          68 (41·7)

    Bone                                                                          26 (31·3)          69 (42·3)

  Prior treatment regimens, n (%)                                                                    

    0                                                                             16 (19·3)          0

    1                                                                             38 (45·8)          26 (16·0)

    2                                                                             16 (19·3)          45 (27·6)

    3                                                                             7 (8·4)            35 (21·5)

    ≥4                                                                            6 (7·2)            57 (35·0)

  Median time from initial diagnosis to initiation of ceritinib, months (range)   8·1 (1·0--109·3)   21·2 (2·4--174·2)
  -----------------------------------------------------------------------------------------------------------------------------------------------------

ALK=anaplastic lymphoma kinase. NSCLC=non-small-cell lung cancer.

All received crizotinib; five patients received the investigational ALK inhibitor CH5424802 after crizotinib.

###### 

Investigator-assessed whole-body responses for all patients with *ALK*-rearranged NSCLC receiving ceritinib 750 mg/day (N=246)

  Efficacy parameter                        ALKi-naïve (n=83)          ALKi-pretreated (n=163)
  ----------------------------------------- -------------------------- --------------------------
  Whole-body responses                                                 
  Complete response, n (%)                  1 (1·2)                    3 (1·8)
  Partial response, n (%)                   59 (71·1)                  89 (54·6)
  Stable disease, n (%)                     14 (16·9)                  29 (17·8)
  Progressive disease, n (%)                0                          16 (9·8)
  Unknown, n (%)                            9 (10·8)                   26 (16·0)
  Overall response rate, n (%) \[95% CI\]   60 (72·3) \[61·4--81·6\]   92 (56·4) \[48·5--64·2\]
  DOR, median \[95% CI\] (months)           17·0 \[11·3--NE\]          8·3 \[6·8--9·7\]
    12-month DOR, %                         64·3 \[48·7--76·3\]        25·6 \[ 16·0--36·3\]
  PFS, median \[95% CI\] (months)           18·4 \[11·1--NE\]          6·9 \[5·6--8·7\]
    12-month PFS, %                         62·3 \[50·0--72·4\]        27·2 \[19·8--35·1\]
  OS, median \[95% CI\] (months)            NE \[19·61-NE\]            16·7 \[14·8--NE\]
    12-month OS, %                          83·0 \[72·4--89·8\]        67·2 \[58·9--74·1\]

ALK=anaplastic lymphoma kinase. DOR=duration of response. NSCLC=non-small-cell lung cancer. OS=overall survival. PFS=progression-free survival.

###### 

Retrospective analyses of intracranial responses in patients with *ALK*-rearranged NSCLC with baseline brain metastases and evaluable MRI/CT scans (in all patients and as a function of prior radiotherapy to the brain)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Efficacy parameter                                                                                                      ALKi-naïve       ALKi-pretreated                                               
  ----------------------------------------------------------------------------------------------------------------------- ---------------- ----------------- ----------- ---------------- -------------- -----------
  Intracranial response in all patients with baseline brain metastases (measurable and non-measurable) by MRI/CT (N=94)                                                                                  

                                                                                                                          All NSCLC\       No prior RT\      Prior RT\   All NSCLC\       No prior RT\   Prior RT\
                                                                                                                          (n=19)           (n=8)             (n=11)      (n=75)           (n=23)         (n=52)

  Complete response, n                                                                                                    3 (15·8%)        1                 2           4 (5·3%)         2              2

  Partial response, n                                                                                                     5 (26·3%)        3                 2           10 (13·3%)       3              7

  Stable disease[\*](#TFN5){ref-type="table-fn"}, n                                                                       7 (36·8%)        3                 4           35 (46·7%)       10             25

  Progressive disease, n                                                                                                  0 (0·0%)         0                 0           12 (16·0%)       5              7

  Unknown[\#](#TFN6){ref-type="table-fn"}, n                                                                              4 (21·1%)        1                 3           14 (18·7%)       3              11

  IDCR, n (%)\                                                                                                            15 (78·9)\       N/A               N/A         49 (65·3)\       N/A            N/A
  \[95% CI\]                                                                                                              \[54·4--93·9\]                                 \[53·5--76·0\]                  

  Intracranial DOR, median\                                                                                               NE\              N/A               N/A         6·9\             N/A            N/A
  \[95% CI\] (months)                                                                                                     \[5·6--NE\]                                    \[2·9--NE\]                     

                                                                                                                                                                                                         

  Intracranial response in patients with measurable baseline brain metastases by MRI/CT (N=36)                                                                                                           

                                                                                                                          All NSCLC\       No prior RT\      Prior RT\   All NSCLC\       No prior RT\   Prior RT\
                                                                                                                          (n=8)            (n=4)             (n=4)       (n=28)           (n=7)          (n=21)

  Complete response (CR), n                                                                                               0 (0·0%)         0                 0           0 (0·0%)         0              0

  Partial response (PR), n                                                                                                5 (62·5%)        3                 2           10 (35·7%)       3              7

  Stable disease (SD), n                                                                                                  0 (0·0%)         0                 0           7 (25·0%)        1              6

  Progressive disease (PD), n                                                                                             0 (0·0%)         0                 0           6 (21·4%)        2              4

  Unknown, n                                                                                                              3 (37·5%)        1                 2           5 (17·9%)        1              4

  OIRR (CR+PR), n (%)\                                                                                                    5 (62·5)\        N/A               N/A         10 (35·7)\       N/A            N/A
  \[95% CI\]                                                                                                              \[24·5--91·5\]                                 \[18·6--55·9\]                  

  IDCR (CR+PR+SD), n (%)\                                                                                                 5 (62·5)\        N/A               N/A         17 (60·7)\       N/A            N/A
  \[95% CI\]                                                                                                              \[24·5--91·5\]                                 \[40·6--78·5\]                  

  Intracranial DOR, median\                                                                                               8·2\             N/A               N/A         11·1\            N/A            N/A
  \[95% CI\] (months)                                                                                                     \[5·6--NE\]                                    \[2·8--NE\]                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALK=anaplastic lymphoma kinase. CI=confidence interval. CT=computed tomography. DOR=duration of response. IDCR=intracranial disease control rate. MRI=magnetic resonance imaging. N/A=non-applicable. NSCLC=non-small-cell lung cancer. OIRR=overall intracranial response rate. RT=radiotherapy.

Non-CR/non-PD in patients with non-measurable brain lesions at baseline.

A response was listed as unknown if all post-baseline assessments had overall response as unknown (n=5), there was no valid post-baseline assessment (n=1), assessment of PD was considered too late (e.g. no valid assessment before week 12; n=3), or assessment of SD was too early (e.g. assessed before day 42 with no further valid assessment; n=9).

###### 

Adverse events occurring at grades 1--2 in ≥10% or at grade 3 or grade4[a](#TFN7){ref-type="table-fn"} in ≥2% of patients with *ALK*-rearranged NSCLC

  Adverse event                          Patients with *ALK*-rearranged NSCLC treated with 750 mg/day (N=246)               
  -------------------------------------- ---------------------------------------------------------------------- ----------- ---------
  Diarrhoea                              198 (80.5)                                                             15 (6.1)    0 (0.0)
  Nausea                                 190 (77.2)                                                             15 (6.1)    0 (0.0)
  Vomiting                               139 (56.5)                                                             11 (4.5)    0 (0.0)
  Fatigue                                94 (38.2)                                                              12 (4.9)    0 (0.0)
  Abdominal pain                         91 (37.0)                                                              3 (1.2)     0 (0.0)
  Decreased appetite                     89 (36.2)                                                              4 (1.6)     0 (0.0)
  Constipation                           75 (30.5)                                                              0 (0.0)     0 (0.0)
  Cough                                  71 (28.9)                                                              0 (0.0)     0 (0.0)
  Abdominal pain, upper                  57 (23.2)                                                              2 (0.8)     0 (0.0)
  Dyspnoea                               52 (21.1)                                                              9 (3.7)     1 (0.4)
  Back pain                              49 (19.9)                                                              1 (0.4)     0 (0.0)
  Headache                               47 (19.1)                                                              4 (1.6)     0 (0.0)
  Asthenia                               45 (18.3)                                                              2 (0.8)     0 (0.0)
  Weight decreased                       41 (16.7)                                                              4 (1.6)     0 (0.0)
  Insomnia                               37 (15.0)                                                              0 (0.0)     0 (0.0)
  Pyrexia                                37 (15.0)                                                              0 (0.0)     0 (0.0)
  Musculoskeletal pain                   36 (14.6)                                                              0 (0.0)     0 (0.0)
  Rash                                   33 (13.4)                                                              0 (0.0)     0 (0.0)
  Dizziness                              31 (12.6)                                                              0 (0.0)     0 (0.0)
  Dyspepsia                              30 (12.2)                                                              1 (0.4)     0 (0.0)
  Arthralgia                             26 (10.6)                                                              0 (0.0)     0 (0.0)
  Musculoskeletal chest pain             26 (10.6)                                                              0 (0.0)     0 (0.0)
  Anaemia                                18 (7.3)                                                               12 (4.9)    0 (0.0)
  Pneumonia                              13 (5.3)                                                               12 (4.9)    0 (0.0)
  Convulsion                             7 (2.8)                                                                7 (2.8)     1 (0.4)
  Pneumonitis                            1 (0.4)                                                                6 (2.4)     1 (0.4)
  Respiratory failure                    0 (0.0)                                                                1 (0.4)     5 (2.0)
  **Laboratory Abnormalities**                                                                                              
  Aspartate aminotransferase increased   56 (22.8)                                                              20 (8.1)    5 (2.0)
  Blood creatinine increased             42 (17.1)                                                              0 (0.0)     0 (0.0)
  Alanine aminotransferase increased     36 (14.6)                                                              66 (26.8)   7 (2.8)
  Blood alkaline phosphatase increased   31 (12.6)                                                              13 (5.3)    0 (0.0)
  Hypokalaemia                           17 (6.9)                                                               10 (4.1)    1 (0.4)
  Amylase increased                      10 (4.1)                                                               7 (2.8)     1 (0.4)
  Hyponatraemia                          8 (3.3)                                                                11 (4.5)    0 (0.0)
  Hypophosphataemia                      8 (3.3)                                                                8 (3.3)     0 (0.0)
  Lipase increased                       8 (3.3)                                                                13 (5.3)    3 (1.2)
  Gamma-glutamyl transferase increased   7 (2.8)                                                                6 (2.4)     1 (0.4)
  Hyperglycaemia                         6 (2.4)                                                                12 (4.9)    3 (1.2)

Grade 5 adverse events were not specifically recorded, per the protocol. However, there were two deaths during the study that were considered to be related to study drug: one from interstitial lung disease and the other from multi-organ failure.

ALK=anaplastic lymphoma kinase. NSCLC=non-small-cell lung cancer.
